Zusammenfassung
Die häufigsten Komplikationen bei Peritonealkarzinose sind maligner Aszites, intestinale Obstruktion und chronische Schmerzen. Bei malignem Aszites ist HIPEC präventiv und therapeutisch effektiv. Die bislang beste Therapie ist der trifunktionale Antikörper Catumaxomab, der signifikante Effekte zeigte und durch die EMA für die Indikation maligner Aszites zugelassen wurde. Die intestinale Obstruktion ist chirurgisch schwierig zu behandeln. Eine chirurgische Indikation ergibt sich nur bei klar lokalisierbaren Stenosen. Komplikationen bei HIPEC sind durch die chirurgische Morbidität bzw. durch den Einsatz der Chemotherapie bedingt. Für die PIPAC-Therapie sind aktuell keine spezifischen Nebenwirkungen beschrieben. Die intraperitoneale Immuntherapie ist in erster Linie durch eine SIRS-Reaktion begleitet.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA (2013) Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Onco 20: 2311–2316
Burges A, Wimberger P, Kumper C, et al. (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13: 3899–3905
Dagbert F, Thievenaz R, Decullier E, et al. (2016) Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23: 1980–1985
Downs-Canner S, Ding Y, Magge DR, et al. (2015) A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol 22: 1651–1657
Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98: 263–267
Feuer DJ, Broadley KE (1999) Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol 10: 1035–1041
Feuer DJ, Broadley KE, Shepherd JH, Barton DP (1999) Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecologic oncology, 75: 313–322
Fujiwara Y, Takiguchi S, Nakajima K, et al. (2012) Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 105: 38–42
Girshally R, Demtroder C, Albayrak N, Zieren J, Tempfer C, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14: 253
Gupta DR, Sangha H, Khanna R (2012) Chemical peritonitis after intraperitoneal sodium thiosulfate. Perit Dial Int 32: 220–222
Heiss MM, Strohlein MA, Jager M, et al. (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117: 435–443
Heiss MM, Murawa P, Koralewski P, et al. (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 127: 2209–2221
Laval G, Marcelin-Benazech B, Guirimand F, et al. (2014) Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Managent 48: 75–91
Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155: 219–225
Lindhofer H, Menzel H, Gunther W, Hultner L, Thierfelder S (1996) Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 88: 4651–4658
Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437–446
Mariani P, Blumberg J, Landau A, et al. (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 30: 4337–4343
Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM (2016) Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery. Ann Surg Oncol 23: 1461–1467
Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J (2009) Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 99: 9–15
Romeo M, de Los LGM, Cuadra Urteaga JL, et al. (2016) Outcome prognostic factors in inoperable malignant bowel obstruction. Support Care Cancer 24: 4577–4586
Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526–2534
Schwarz L, Votanopoulos K, Morris D, et al. (2016) Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study. Ann Surg 263: 369–375
Ströhlein MA, Heiss MM (2007) Immunotherapy of peritoneal carcinomatosis. Cancer Treat Res 134: 483–491
Ströhlein MA, Heiss MM (2010) The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future oncology (London, England) 6: 1387–1394
Ströhlein M, Heiss M (2011) Catumaxomab treatment of peritoneal carcinomatosis from EpCAM-positive cancer: identification of biomarkers with relevance for improved efficacy and survival. J Clin Oncol 29
Sugarbaker PH, Alderman R, Edwards G, et al. (2006) Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 13: 635–644
Tsubamoto H, Takeuchi S, Ito K, et al. (2015) Feasibility and efficacy of intraperitoneal docetaxel administration as salvage chemotherapy for malignant gynaecological ascites. J Obstet Gynaecol 35: 69–73
Went P, Lugli A, Meier S, et al. (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122–128
Went P, Vasei M, Bubendorf L, et al. (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94: 128–135
Zeidler R, Reisbach G, Wollenberg B, et al. (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163: 1246–1252
Zeidler R, Mysliwietz J, Csanady M, et al. (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83: 261–266
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Ströhlein, M. (2018). IPEC, HIPEC, PIPAC, bidirektionale Chemotherapie und Immuntherapie bei Komplikationen der Peritonealkarzinose. In: Rau, B., Piso, P., Königsrainer, A. (eds) Peritoneale Tumoren und Metastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54500-3_30
Download citation
DOI: https://doi.org/10.1007/978-3-662-54500-3_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-54499-0
Online ISBN: 978-3-662-54500-3
eBook Packages: Medicine (German Language)